We Give Our Utmost Care to

Better Safeguard Patients’ Health

Our Dedication to Patients is Reflected in Every Detail in Manufacturing and Operations
Product Profile
Our heparin products include APIs and preparations. Hepalink’s enoxaparin sodium injection is globally recognized for its quality, and has thus far sold over 400 million doses in Europe.The product is currently being sold in over 40 countries and regions including the U.S. and the EU, and has been included into national insurance programs in all 13 member countries of the EU, United Kingdom, and Switzerland.
API Products
Finished Dose Products
2000 AXaIU and 4000 AXaIU injections: Prophylaxis of venous thromboembolic diseases (prevent intra-vein thrombosis), especially thrombosis related with orthopedics and general surgery. 6000 AXaIU,8000 AXaIU , and 10000 AXaIU injectionsTreatment of the existing deep venous thrombosis (DVT) with no serious clinic symptoms accompanied with or without pulmonary embolism (PE), not including surgery or thrombolytics needed pulmonary embolism (PE). · Treatment of unstable angina pectoris and non-Q-wave myocardial infarction, when concurrently administered with Aspirin. · Used in extra-corporeal circulation of hemodialysis to prevent the formation of thrombus. · Treatment of acute ST-segment elevation myocardial infarction (STEMI); combined with thrombolytics for percutaneous coronary intervention (PCI) treatment.
Inhixa is indicated in adults for: Prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoingorthopaedic or general surgery including cancer surgery.Prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism. ·Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), excluding PE likely to require thrombolytic therapy or surgery. ·Prevention of thrombus formation in extra corporeal circulation during haemodialysis.
Produkt leczniczy Neoparin jest wskazany do stosowania u osób doroslych w: Zapobieganiu żylnej chorobie zakrzepowo-zatorowej u pacjentow chirurgicznych z grup umiarkowanego i wysokiego ryzyka, w szczególności poddawanych zabiegom chirurgicznym ortopedycznym lub zabiegom w chirurgii ogólnej, w tym zabiegom w chirurgii onkologicznej. ·Zapobieganiu żylnej chorobie zakrzepowo-zatorowej u pacjentów internistycznych z ostrymi schorzeniami (takimi jak ostra niewydolność serca, niewydolność oddechowa, ciężkie zakażenia lub choroby reumatyczne) i ograniczoną mobilnością, narażonych na podwyższone ryzyko żylnej choroby zakrzepowo-zatorowej. ·Leczeniu zakrzepicy żył głębokich (ZŻG) i zatorowości płucnej (ZP), z wyłączeniem zatorowości płucnej, która może z dużym prawdopodobieństwem wymagać leczenia trombolitycznego lub zabiegu operacyjnego.
Heparin Sodium Injection
Heparin sodium injection is indicated for: Prophylaxis and treatment of venous thrombosis and pulmonary embolism.Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease.Atrial fibrillation with embolization.Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation).Prevention of clotting in arterial and cardiac surgery.Prophylaxis and treatment of peripheral arterial embolism.Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures.
第一页 上一页 1 下一页 最后一页